{"DataElement":{"publicId":"2005448","version":"4","preferredName":"CTC Adverse Event Fibrinogen Grade","preferredDefinition":"in CTC category Coagulation, assessment of the severity of a fibrinogen count adverse event using a graded scale.","longName":"CTC_AE_FBG_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192410","version":"1","preferredName":"CTC Adverse Event Fibrinogen Description","preferredDefinition":"information related to the grade or description of a CTC adverse event of fibrinogen.","longName":"CTC_AE_FBG_DESC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207319","version":"1","preferredName":"Fibrinogen Description ","preferredDefinition":"Fibrinogen; a fibrillar protein present in blood plasma; it converts to fibrin when blood clots.:Description; a statement that represents something in words.","longName":"C25736:C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrinogen","conceptCode":"C25736","definition":"A fibrillar protein present in blood plasma; it converts to fibrin during the process of blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1FF7-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9416785-0FEE-6408-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017648","version":"3","preferredName":"CTC Adverse Event Fibrinogen Grade","preferredDefinition":"in CTC category Coagulation, assessment of the severity of a fibrinogen count adverse event using a graded scale.","longName":"CTC_AE_FBG_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E86-6EFC-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"1","valueDescription":"<1.0 - 0.75 x LLN or <25% decrease from baseline","ValueMeaning":{"publicId":"2566336","version":"1","preferredName":"<1.0 - 0.75 x LLN or <25% decrease from baseline","longName":"2566336","preferredDefinition":"<1.0 - 0.75 x LLN or <25% decrease from baseline","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D02D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E88-6EFC-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"<0.75 - 0.5 x LLN or 25 - <50% decrease from baseline","ValueMeaning":{"publicId":"2566337","version":"1","preferredName":"<0.75 - 0.5 x LLN or 25 - <50% decrease from baseline","longName":"2566337","preferredDefinition":"<0.75 - 0.5 x LLN or 25 - <50% decrease from baseline","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D02E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E8A-6EFC-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"<0.25 x LLN or 75% decrease from baseline or absolute value <50 mg/dL","ValueMeaning":{"publicId":"2566339","version":"1","preferredName":"<0.25 x LLN or 75% decrease from baseline or absolute value <50 mg/dL","longName":"2566339","preferredDefinition":"<0.25 x LLN or 75% decrease from baseline or absolute value <50 mg/dL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D030-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E8C-6EFC-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"<0.5 - 0.25 x LLN or 50 - <75% decrease from baseline","ValueMeaning":{"publicId":"2566338","version":"1","preferredName":"<0.5 - 0.25 x LLN or 50 - <75% decrease from baseline","longName":"2566338","preferredDefinition":"<0.5 - 0.25 x LLN or 50 - <75% decrease from baseline","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D02F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E8E-6EFC-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"0","valueDescription":"WITHIN NORMAL LIMITS","ValueMeaning":{"publicId":"2564104","version":"1","preferredName":"WITHIN NORMAL LIMITS","longName":"2564104","preferredDefinition":"a reported laboratory value that is within the institutional range of values for normal","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C775-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-01-21","endDate":null,"createdBy":"PWEST","dateCreated":"2003-01-21","modifiedBy":"PWEST","dateModified":"2003-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C42B5B1A-7E90-6EFC-E034-0003BA12F5E7","beginDate":"2003-01-21","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208073","version":"1","preferredName":"Fibrinogen Grade","preferredDefinition":"Fibrinogen; a fibrillar protein present in blood plasma; it converts to fibrin when blood clots.:Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"C25736:C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrinogen","conceptCode":"C25736","definition":"A fibrillar protein present in blood plasma; it converts to fibrin during the process of blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3C76-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C42B5B1A-7E82-6EFC-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-05","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[{"name":"2005448","type":"HISTORICAL_CDE_ID","context":"CTEP"}],"ReferenceDocuments":[{"name":"CTC Adverse Event Fibrinogen","type":"Preferred Question Text","description":"CTC Adverse Event Fibrinogen Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Fibrinogen Grade","url":null,"context":"CTEP"},{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"}],"origin":"CTCAE:Common Terminology Criteria for Adverse Events v3.0","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C42B3BC8-D7F0-6F00-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"CHANGM","dateCreated":"2003-08-05","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}